FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Lowers Rating On Shares Of Boston Scientific Corporation To Hold From Buy

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target to $56 from $100 on 14.4x our 2027 EPS estimate, a discount to BSX's five-year historical forward P/E average. We reduce our 2026 EPS view to $3.32 from $3.40 as we lower our quarterly estimates on margin concerns. We also lower our 2027 EPS forecast to $3.90 from $4.04. While we see healthy growth in procedures and diagnostics in the long run, we are uncertain about the near-term evolution of elective surgeries due to softening demand and weakening consumer sentiment in the U.S., which hit an all-time low in May amid a complex macroeconomic environment. At the same time, we continue to see tariffs as a considerable pressure point on the cost side, as many companies in the industry have global supply chains, while competition is intensifying between BSX, Medtronic, J&J, and Abbott, in our view. Amid these challenges coupled with margin pressures stemming from rising raw material costs and supply chain challenges, we prefer to remain on the sidelines and lower our view to Hold from Buy.

Related Articles

Research

Research Alert: CFRA Downgrades Rating On Shares Of Palo Alto Networks Inc. To Buy From Strong Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We up our target to $280 from $193, on a P/E of 68x our FY 27 EPS estimate. We keep our FY 26 EPS view at $3.70 but lift our FY 27 EPS forecast to $4.12 from $4.01. PANW continues to strengthen its portfolio. We highlight the increased focus on agentic capabilities, such as the acquisition of Koi (completed in April) for its Agentic Endpoint Security tools, and its recent launch of Idira, a next-gen Identity Security platform that enhances Privilege Access Management with agentic functionality. PANW also announced its intent to acquire Portkey to enable users to centrally manage AI Agents. With Agentic adoption scaling rapidly, we believe CISOs have to allocate more budget to agentic security, an area where most are lacking in solutions. Additionally, Idira's launch represents the GTM execution of its CyberArk acquisition, and we expect cross-platform selling to start ramping. That said, shares have rallied substantially the last month (+48%) and we see a less attractive risk-reward at current multiples.

$PANW
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Dexcom

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month price target remains $67, 26x our 2026 EPS estimate (raised by $0.09 to $2.58; 2027 estimate raised by $0.06 to $3.05), below DXCM's one-year historical forward average of 33.5x and well below long-term term historical averages to reflect stronger competition within the continuous glucose monitoring space and uncertain insurance coverage and rebate dynamics, in our view. On May 14, DXCM announced a collaboration with activist investment firm Elliott Management, which holds a meaningful equity stake in DCXM (undisclosed amount), based on DXCM's recent press release. Among other potential changes, DXCM is making changes to the composition of its Board of Directors. The company also revealed some details about the upcoming G8 device, which is 50% smaller than the G7 and offers superior performance in terms of speed and real-time sensing capabilities. The G8 is expected to launch toward the end of 2027 or beginning of 2028.

$DXCM
Research

Research Alert: CFRA Maintains Strong Buy Rating On Shares Of Globant S.a.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our price target by $10 to $82, based on 13x our 2026 EPS view, well below GLOB's three-year average (~23x) given industrywide competitive pressure from agentic AI. We lower our 2026 EPS estimate by $0.06 to $6.26 and increase 2027 by $0.04 to $6.76. GLOB continues to lean into agentic AI orchestration, which should help it shake some of the market's fears of extinction for traditional service delivery models. AI Pods grew ARR by 57% Q/Q to $33M in Q1, with GLOB now deploying this model at 40% of its top 20 customers (up from 30% in 2025) and with a "clear path to coverage" at 70% of its top 20, commentary that we think sets it up nicely to exceed its targeted midpoint of $80M in AI Pods ARR by year-end 2026. Q1 brought continued signs of resilience, with Q/Q and Y/Y growth across its top 10, top 5, and top client (Disney, 8.9% of sales) and with GLOB reiterating its full-year guidance midpoints despite elevated uncertainty, an encouraging result after 2025 brought valuation-damaging guidance cuts.

$GLOB